SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Biotechnology & Drugs
An SI Board Since February 2001
Posts SubjectMarks Bans
232 7 0
Emcee:  2MAR$ Type:  Moderated
Introduction Compact
Biotech & Drugs Investor Thread
is a periodic series of updates of the
changing Biotech and Pharmaceutical world
we live in and the companies
that are going to profit
from these changes.

Will try to focus upon developing more in-depth
analyses of important research themes occurring
in the Biotechnology industry.

With the intent to sift through
the realms of new Biotech information trying to stay
current with some of the more important
scientific and corporate developments.
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
232Dr. Rajiv Khosla has been appointed Chief Operating Officer and Chief ScientificSmartStocks-5/15/2013
231Well, that didn't work. lol.kenhott-4/30/2008
230Merck Shares ($28) Continue to Drop in Heavy Trading, First Full Day After Vioxx2MAR$-8/22/2005
229OSIP <B>+$52....</b> ($38-$92) !! Successful Tarceva Study Sends Sha2MAR$-4/27/2004
228SEPR Shares Soar ($28-$45) 45% following conditional OK for less addictive insom2MAR$-3/1/2004
227***1/14 DNA $90~$110~$107 Genentech beats by 2 cents (DNA) 90.67 +0.42: Reports2MAR$-2/28/2004
226** 1/28 $17-$14 CRA beats by $0.07, ex items (CRA) 15.30: Co reports a loss of 2MAR$-2/28/2004
2251/28 CHIR $55~$48 CHIR reports in-line Q4 EPS (CHIR) 51.25 +0.36: Reports Q4 (De2MAR$-2/28/2004
224** 2/12 $52~$58 CEPH reports in line, beats on revs; guides for Q1 & Y04 (CE2MAR$-2/28/2004
2231/12 $47-$40-$41 Celgene plunges in reaction to guidance (CELG) 44.69 -1.92: Co2MAR$-2/28/2004
2221/22 Amgen misses by $0.02, ex items (AMGN) 62.00 -0.81: Reports Q4 (Dec) earnin2MAR$-2/28/2004
221**1/28 AFFX ($27~$33 )beats by $0.02; guides Y04 revs above consensus (AFFX) 27.2MAR$-2/28/2004
220Jan 22 SEPR $28~$26 beats by $0.30, beats on revs (SEPR) 27.38: Reports Q4 (Dec2MAR$-2/28/2004
219** AMGN ($63 $66) 4th-Quarter Net Rose 20% on Solid Drug Sales Thursday January2MAR$-1/29/2004
218*** AFFX ($25~$31) posts sharply higher profit Wednesday January 28, 4:31 pm ET 2MAR$-1/29/2004
217<b>********************************************2MAR$-1/27/2004
216S&P sees biotech sector growth topping 20 percent Tuesday November 25, 3:55 2MAR$-11/25/2003
215So Stay tuned --------->to Bellweather DNA's drug -->**Avastin ( advan2MAR$-11/25/2003
214yet--->Genentech Expects Avastin Approval Tuesday November 25, 6:48 pm ET By2MAR$-11/25/2003
213Now in Nov ---->Genentech drug Avastin study falls short . stock falters By2MAR$-11/25/2003
212Yet just days before --->UPDATE - Early Genentech, Idec cancer drug data lack2MAR$-11/25/2003
211Study Shows Success in a New Use of BIIB/DNA's ---->Rituxan Wednesday Nov2MAR$-11/25/2003
210Boehringer Ingelheim and Genentech Announce Initiation of a Clinical Trial Evalu2MAR$-11/25/2003
209And the day following BIIB/DNA ---->News flow on drugs keeps <i><b&g2MAR$-11/25/2003
208and more --->DNA Follow-up Data from Phase II Study of Rituxan as a Potential2MAR$-11/25/2003
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News